Research Progress on the Correlation of Atopic Dermatitis with Gut Microbiota.

Atopic dermatitis (AD) is a common skin disease, the pathogenesis of which has not been fully elucidated. The gut microbiota is the largest micro-ecosystem in the human body that affects the immune system and skin barrier function. Recent studies have shown that in addition to the environmental factors, skin barrier, genetic factors and immune response, gut microbiota disturbance may also cause AD. This review described the correlation of AD with gut microbiota and existing research status of AD treatment via targeting gut microbiota.

Efficacy of dupilumab in the treatment of severe vulvar pruritus associated with lichen sclerosus et atrophicus: a case report.

Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory skin lesion with an undefined cause. It is more commonly found in the genital area, particularly in adolescents, premenopausal women and postmenopausal women. LSA is difficult to treat and often recurs. The primary treatment for LSA involves the administration of potent topical corticosteroids. Dupilumab is increasingly being used for the treatment of itching in non-atopic dermatitis patients but there are few reports on its use for the treatment of LSA. Here, we present a case of LSA in a 61-year-old woman with extensive vulvar itching. Over four months of dupilumab therapy, significant therapeutic effects were observed, including vulvar skin thinning and pruritus relief without adverse reactions.

Characteristics of gut microbiota and serum metabolism in patients with atopic dermatitis.

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects 15%-30% of children and 10% of adults globally, with its incidence being influenced by genetic, environmental, and various other factors. While the immune plays a crucial role in the development, the composition of gut microbiota and serum metabolites also contribute to its pathogenesis. SUBJECT: Study the characteristics of gut microbiota and serum metabolites in patients with atopic dermatitis METHOD: In this study, we collected stool and serum samples from 28 AD patients and 23 healthy individuals (NC) for metagenomic sequencing of gut microbiota and non-targeted metabolomic sequencing of serum. RESULT: Our results revealed a lower diversity of gut microbiota in the AD group compared to the NC group. The predominant Phylum in AD patients were Bacteroidetes, Pseudomonas, and Verrucomicrobia, with the most dominant bacterial genus being Faecalibacterium. At the species level, Prevotella copri and Faecalibacterium prausnitzii were found to be the most abundant bacteria. Significant differences in serum metabolite profiles were observed between NC and AD patients, with noticeable variations in metabolite expression levels. The majority of metabolites in the serum of AD patients exhibited low expression, while a few showed high expression levels. Notably, metabolites such as Cholesterol glucuronide, Styrene, Lutein, Betaine, Phosphorylcholine, Taurine, and Creatinine displayed the most pronounced alterations. CONCLUSION: These findings contribute to a further understanding of the complexities underlying this disease.

Digitalization in prefabricated constructions and reducing carbon emission: empirical evidence from China.

Taking the implementation of digitalization in prefabricated constructions (DPC) as an exogenous shock, this study utilizes provincial panel data of China from 1997 to 2019, and uses the difference-in-differences model to identify the causal effect of DPC on carbon emissions in the construction industry (CECI). This study shows that DPC effectively reduces CECI with the results withstanding rigorous testing, including parallel trend tests, placebo tests, and a heterogeneous time-varying treatment test based on Bacon decomposition and the DIDm approach. The mechanism test confirms that DPC reduces CECI through two channels, which are improving existing building technologies and promoting better management capabilities. At the same time, further analyses show that the carbon emissions reduction effect of DPC is more pronounced in regions with a higher degree of marketization, financial development, human capital and environmental regulation. This study contributes to understanding the underlying mechanisms between DPC and CECI, providing new insights for the deeper integration of digital technologies and the construction industry. It offers new avenues for revitalizing the construction sector and facilitating achieving global carbon emissions reduction goals.

Case report: Treatment of psoriasiform dermatitis in patients with malignancy.

Psoriasis and atopic dermatitis (AD) are prevalent inflammatory skin disorders, each stemming from diverse factors, and characterized by recurring episodes. In certain complex cases, the clinical and pathological features exhibit overlapping and atypical characteristics, making accurate clinical diagnosis and targeted treatment a challenge. Psoriasiform dermatitis is the term used to describe such cases. Moreover, when patients have a history of malignancy, the situation becomes even more intricate, resulting in limited treatment options. Biologic therapies have transformed the management of immune-mediated inflammatory diseases, including psoriasis and AD. Meanwhile, the safety of biologics in special populations, especially among patients with a history of malignancy, should be underlined. The selective Janus kinase 1 (JAK1) inhibitor abrocitinib has been approved for the treatment of AD and has showed satisfying efficacy and safety in the treatment of psoriasis in clinical trials. Although unreported, JAK1 inhibitors are thought to have the potential to increase the risk of potential tumors. Apremilast, an oral phosphodiesterase (PDE)-4 inhibitor, is approved for moderate to severe plaque psoriasis. It has been investigated for its efficacy in AD, and is not contraindicated in malignancy. This report presents three cases of psoriasiform dermatitis in patients with a history of malignancy, showcasing significant improvement following treatment with systemic glucocorticoid, abrocitinib, or apremilast.

(-)-Epigallocatechin-3-Gallate Protects Human Skin Fibroblasts from Ultraviolet a Induced Photoaging.

Background: Ultraviolet (UV) is a common stressor of skin and repeated UVA radiation contributes to photoaging. (-)-Epigallocatechin-3-Gallate (EGCG), as the major polyphenol that is found in green tea, and catechins and have shown considerable antioxidant capacity. Purpose: Our study aims to explore the effects of EGCG on UVA-induced skin photoaging process and associated mechanisms. Methods: In this study, human skin fibroblasts (HSFs) were treated with UVA and EGCG, and subsequent changes in cell morphology, telomeres, antioxidant capacity, cell cycle, and related genes were evaluated to examine the role and mechanisms of EGCG in delaying skin photoaging. Results: HSF exposed to UVA underwent an increase in aging-related biomarkers and telomere shortening. Also, UVA radiation inhibited the secretion of transforming growth factor-beta1 (TGF-ß1), induced cell cycle arrest, down-regulated antioxidant enzymes, and promoted the accumulation of oxidative product malondialdehyde (MDA) to cause further damage to cells. Increased expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinase-1 (TIMP-1), p66 at mRNA levels were also observed after UVA irradiation. EGCG treatment effectively inhibited above damage processes caused by UVA radiation in HSF. Conclusion: Our study indicated that the potential mechanism of EGCG retarding photoaging is closely related to its powerful antioxidant effects and the ability to regulate the expression of related genes, and the usage of EGCG will be a potential strategy in preventing skin photoaging induced by UVA radiation.

Clinical observation and analysis of skin reactions caused by COVID-19 vaccination.

The novel coronavirus disease 2019 (COVID-19) vaccination is now an essential strategy for controlling the COVID-19 epidemic. This study included 132 cases of adverse skin reactions after the injection of COVID-19 vaccination from January 2021 to January 2022. The rate of adverse skin reactions after the 1st, 2nd, and 3rd doses of the COVID-19 vaccine were 52%, 40%, and 8% of total adverse skin reactions, respectively. The Urticaria-like rash was the most common manifestation of all adverse skin reactions, accounting for 40.15% of all adverse reactions. The Eczema-like rash was 27.27%. The rates of adverse skin reactions after vaccination with the COVID-19 vaccine in patients with a previous skin disease was 12.12%. Other rare skin adverse reactions after COVID-19 vaccination included herpes zoster, pityriasis rosea, erythema multiforme, chickenpox, herpes simplex, psoriasis, erythrodermatitis, arthus reaction, lichen planus recurrence, measles-like rash, frostbite rash, seborrhea, and vitiligo. There were 23 cases of adverse skin reactions in the same individual after two doses of COVID-19 vaccine. There were three cases of adverse skin reactions in the same person after three doses of the vaccine. Treatment measures are mostly mild regimens, such as oral antihistamines, compounded glycopyrrolate and topical weak to moderately potent corticosteroid creams. The total duration of these skin adverse reactions ranged from 2 weeks to 1 month.